ASIT biotech announced that it has successfully placed senior, unsecured Convertibles Notes, for a total amount of EUR 9.225 million via a private placement, in the context of a book building procedure organized by the Company and Bryan, Garnier & Co Limited as Bookrunner. The company intends to use the net proceeds of the transaction for the clinical development of its product candidates: Completion of ABT011 Phase III (gp-ASIT+™, a 3-week adjuvant-free immunotherapy treatment for grass pollen rhinitis), including data package preparation for filing. Preparation of the study on a second-year treatment of the patients who finished ABT011, which should begin prior to the 2020 pollen season. Finalization of pre-clinical package for pnt-ASIT+™ in peanut allergy. These notes are divided into two parts with the aim of minimizing the dilution of existing shareholders and limiting the risks for investors: The first part (EUR 5.025 million) is paid-up at issuance to cover the cash needs to the end of 2019, corresponding to the outcome and first results of the Phase III study with gp-ASIT+™. Conversion will take place upon publication of all satisfactory primary endpoints from this ongoing Phase III study (ABT011) with a conversion premium of 15%, and at a conversion price of EUR 1.2680 per share (corresponding to the VWAP over the 30 trading days preceding the February 22, 2019 Board of Directors meeting to which a discount has been added). The second part (EUR 4.2 million) shall be paid-up upon publication of all satisfactory primary endpoints from this ongoing Phase III study. Conversion will take place with a conversion premium of 25%, and at a conversion price equivalent to the issue price of the new ordinary shares of the Company issued in the context of a capital raising to be closed in 2020. The maturity date of the convertible notes is December 31, 2020 and the notes bear an interest rate of 3% per annum. The new shares will have a lock-up period of 6 months.